Cellectis S.A.
CLLS Healthcare Biotechnology
Cellectis S.A.’s revenue for fiscal 2025 (year ended December 2025) was $79.6 million, up 61.7% from fiscal 2024. In the quarter to June 2026, revenue fell 62.1%, EPS grew 8.33%, free cash flow fell 37.0% and total debt was flat, each against the same quarter a year earlier.
Follow CLLS
Cellectis S.A. (CLLS) EV/Sales
As of 16 October 2026, Cellectis S.A. (CLLS) trades at a EV/Sales of 0.2×. Over the past ten years it has ranged from −9.0× (September 2022) to 35.1× (April 2018); the current reading is higher than 19% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.5× | — |
| FY2024 | −0.6× | — |
| FY2023 | 2.8× | 129.02% |
| FY2022 | 1.2× | (76.53%) |
| FY2021 | 5.2× | (53.39%) |
| FY2020 | 11.1× | (38.11%) |
| FY2019 | 18.0× | 68.79% |
| FY2018 | 10.7× | (53.78%) |
| FY2017 | 23.0× | 271.89% |
| FY2016 | 6.2× | (48.13%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.3× | 17.34% |
| Mar 2026 | 2.8× | (38.56%) |
| Dec 2025 | 4.5× | 113.63% |
| Sep 2025 | 2.1× | 358.25% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CRBP Corbus Pharmaceuticals Holdings, Inc. compare | −5.2× |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| AARD Aardvark Therapeutics, Inc. compare | n/m |
| NMRA Neumora Therapeutics, Inc. compare | n/m |
| CLLS Cellectis S.A. | 0.2× |
| EQ Equillium, Inc. compare | 2.0× |
| PTHS Pelthos Therapeutics Inc. compare | 2.7× |
| NTRB Nutriband Inc. compare | 44.7× |
| PMN Promis Neurosciences compare | 11,382× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)